A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 635 participants.
Also called NCT02505334
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 635 participants
- Sponsor
- Registry
-
NCT02505334
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02505334. Randomized; no masking; primary purpose treatment. Start 2015-07-21 (actual); primary completion 2017-05-02 (actual). Results posted on 2018-06-25.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- liraglutide
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02505334- Content hash
37637c186f81565a57ce21cd0b5cdca4a47675d20b5ace23c773d8353838e466